Compare Crispr Therapeutics AG (CRSP) vs ServiceNow Inc (NOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs ServiceNow Inc — how do they compare? Crispr Therapeutics AG trades at $50.54 (market cap $4.97B), while ServiceNow Inc trades at $105.86 (market cap $108.13B). The key difference: ServiceNow Inc is far larger — about 21.8× Crispr Therapeutics AG's market cap. Which is the better fit depends on your goals.
| CRSP | NOW | |
|---|---|---|
Market Cap | $4.97B | $108.13B |
Sector | Health | Technology |
52-Week High | $76.78 | $199.24 |
52-Week Low | $44.34 | $83.00 |
Enterprise Value | $3.32B | $105.38B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
ServiceNow (NOW) trades at $111.26, up 3.3% on the day, with a bullish technical signal and strong fundamental growth. Revenue grew to $13.28B in 2025, with net income of $1.75B, though valuation ratios like P/E of 62.41 are elevated. Recent news highlights AI-driven growth opportunities, with the stock gaining 41% in May 2026 (Fool, 2026-06-03).
The outlook remains positive with an 85.51% analyst buy rating and a $137.41 consensus price target, implying significant upside. Risks include high valuation sensitivity and competitive pressures in enterprise AI. Cash flow trends show operational strength, but 2026 projections indicate potential net outflow, warranting monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About ServiceNow Inc
ServiceNow Inc provides software solutions to structure and automate various business processes via a SaaS delivery model. The company primarily focuses on the IT function for enterprise customers. ServiceNow began with IT service management (ITSM), expanded within the IT function, and more recently directed its workflow automation logic to functional areas beyond IT, notably customer service, HR service delivery, and security operations. ServiceNow also offers an application development platform as a service (PaaS).
Read more on NOW →
